Availability of Menveo (meningococcal ACWY vaccine)
24 March 2017
GSK is experiencing a short-term supply constraint of Menveo® in Australia due to a recent increase in notifications of the meningococcal W strain which is driving increased demand.
Menveo is one of a number of meningococcal ACWY vaccines currently available in Australia.
Menveo is a meningococcal (Groups A, C, W-135 and Y) oligosaccharide CRM197 conjugate vaccine and is not on the National Immunisation Program.
The Meningococcal ACWY vaccine is considered an important vaccine to receive before travelling overseas to where the disease burden is greatest - in the ‘Meningitis Belt’ of Sub-Saharan Africa. This area covers 26 countries from Senegal to Ethiopia. Meningococcal vaccines are required by the Kingdom of Saudi Arabia for pilgrims doing Umra or Hajj.
Recently there has been an increase in cases of Meningococcal W strain in some areas of Australia leading to the introduction of State and Territory-based vaccination programs to protect those most at risk.
GSK is prioritising supply of Menveo to Australian State and Territory-based programs and we are adjusting our forecasts to meet the anticipated increase in demand in Australia.
We regret the inconvenience this may cause people and their families who want the vaccine, as well as pharmacists and doctors. We are working to re-establish supply as a matter of urgency.
Please visit the TGA website for ongoing updates to supply.
For more information, please contact GSK medical information on 1800 033 109 or visit Menveo Consumer Medicine Information
Journalist enquiries, please contact Kim O’Donohue on 0477 322 431